← Back to Screener
Moleculin Biotech, Inc. (MBRX)
Price$2.40
Momentum ScoreD
Favorite Metrics
Price vs S&P 500 (26W)-72.73%
Price vs S&P 500 (4W)-2.82%
VGM Score31.34
Market Capitalization$12.81M
All Metrics
Book Value / Share (Quarterly)$2.85
P/TBV (Annual)1.77x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-4.55
Price vs S&P 500 (YTD)-35.65%
EPS (TTM)$-25.49
10-Day Avg Trading Volume0.32M
EPS Excl Extra (TTM)$-25.49
EPS (Annual)$-28.33
ROI (Annual)-223.64%
Cash / Share (Quarterly)$1.93
ROA (Last FY)-151.68%
EBITD / Share (TTM)$-13.72
ROE (5Y Avg)-129.19%
Cash Flow / Share (Annual)$-7.11
P/B Ratio0.84x
P/B Ratio (Quarterly)0.80x
Net Income / Employee (Annual)$-1,974,100
Net Interest Coverage (TTM)-6.48x
ROA (TTM)-138.76%
EPS Incl Extra (Annual)$-28.33
Current Ratio (Annual)1.41x
Quick Ratio (Quarterly)1.30x
3-Month Avg Trading Volume0.19M
52-Week Price Return-86.09%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.76
52-Week High$24.00
EPS Excl Extra (Annual)$-28.33
CapEx CAGR (5Y)-24.21%
Tangible BV CAGR (5Y)-10.21%
26-Week Price Return-64.81%
Quick Ratio (Annual)1.30x
13-Week Price Return7.14%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)1.38x
Enterprise Value$2.49M
Book Value / Share Growth (5Y)-27.30%
Revenue / Employee (Annual)$0
Cash / Share (Annual)$2.77
3-Month Return Std Dev66.88%
Net Income / Employee (TTM)$-1,784,200
ROE (Last FY)-223.64%
Net Interest Coverage (Annual)-10.97x
EPS Basic Excl Extra (Annual)$-28.33
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-25.49
ROI (TTM)17.93%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$1.21
Price vs S&P 500 (52W)-110.45%
Year-to-Date Return-27.49%
5-Day Price Return-9.09%
EPS Normalized (Annual)$-28.33
ROA (5Y Avg)-90.58%
Month-to-Date Return-13.98%
Cash Flow / Share (TTM)$-0.89
EBITD / Share (Annual)$-22.30
ROI (5Y Avg)-129.19%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-25.49
P/TBV (Quarterly)3.03x
P/B Ratio (Annual)0.46x
Book Value / Share (Annual)$4.69
Price vs S&P 500 (13W)-1.11%
Beta1.82x
Revenue / Share (TTM)$0.00
ROE (TTM)17.93%
52-Week Low$1.79
mGradeD
vgmGradeD
Show chart for
Earnings Surprise History
Q1 26-3.54est. -1.70
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.11
4.11
4.11
4.11
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
MBRXMoleculin Biotech, Inc. | — | — | D | $2.40 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Moleculin Biotech is a clinical-stage biopharmaceutical company developing a portfolio of drug candidates for resistant cancers and viral infections. The company's lead program, Annamycin, is a next-generation anthracycline designed to overcome multidrug resistance while reducing cardiotoxic side effects.